Cholinesterase

What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List

Retrieved on: 
Thursday, August 10, 2023
Cholinesterase, GMG, Efgartigimod alfa, Myasthenia gravis, Neurology, Genentech, UCB, Patient, Physician, Ocular myasthenia, Diagnosis, Neonatal Fc receptor, Horizon, Cholinesterase inhibitor, Pharmaceutical industry, Eculizumab, Ravulizumab

US-based neurologists completed this HIPAA compliant, online chart audit survey among 607 patients with gMG using information exclusively found in their practice’s electronic medical records.

Key Points: 
  • US-based neurologists completed this HIPAA compliant, online chart audit survey among 607 patients with gMG using information exclusively found in their practice’s electronic medical records.
  • Spherix’s sweeping research paints a picture of the gMG treatment journey and the patients who are coping with this devastating neuromuscular condition.
  • The RealWorld Dynamix chart audit study was completed by nearly 150 neurologists and neuromuscular specialists across all regions of the US.
  • Patient charts were submitted by general neurologists seeing as few as 10-20 gMG patients and specialists managing more than 100 gMG patients.

Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia

Retrieved on: 
Thursday, August 10, 2023
Health, Genetics, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Hypersensitivity, Cholinesterase, Nausea, Bethanechol, Bradycardia, Peptic ulcer disease, Asthma, Neuromuscular blocking agents, Cholinergic, Partnership, Alzheimer's disease, Diarrhea, Gastrointestinal tract, IQVIA, Roflumilast, Skin, History, Orthostatic syncope, CNS, Heart block, Dementia, Tablet, Anesthesia, Vomiting, Enzyme inhibitor, Incidence, Patient, Chloride, Gastrointestinal bleeding, Nonsteroidal anti-inflammatory drug, FDA, Relaxation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cholinesterase inhibitor, Safety, Food, Caregiver, Pharmaceutical industry, Residential care, Dietary supplement, Corium, Donepezil, Lotus

Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.

Key Points: 
  • Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
  • The companies expect to file for regulatory approval in some Asian markets later this year.
  • Under the terms of the agreement, Lotus will have exclusive rights to commercialize ADLARITY® in the applicable territory and will be responsible for the regulatory approval process.
  • According to IQVIA data, the market size of donepezil in the 10 markets in the territory is USD 185 Million.

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
Monday, December 12, 2022
Online, Vascular dementia, Geriatrics, Cholinesterase, Conditional sentence, Diagnosis, Drug discovery, Hospital, Dementia, Parkinson's disease dementia, Prevalence, Patient, NMDA, Smoker, Research, COVID-19, Drug development, Pharmacy, Government, Combination, Investment, Growth, Receptor antagonist, Life expectancy, Distribution, Pharmacy Council of India, Consciousness, Medical device, Pharmaceutical industry, Alzheimer's disease

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
Monday, December 12, 2022
Online, Vascular dementia, Geriatrics, Cholinesterase, Conditional sentence, Diagnosis, Drug discovery, Hospital, Dementia, Parkinson's disease dementia, Prevalence, Patient, NMDA, Smoker, Research, COVID-19, Drug development, Pharmacy, Government, Combination, Investment, Growth, Receptor antagonist, Life expectancy, Distribution, Pharmacy Council of India, Consciousness, Medical device, Pharmaceutical industry, Alzheimer's disease

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease

Retrieved on: 
Monday, November 21, 2022
Marketing, ADAS, Inflammation, ANSM, Cell, Cognition, ADAS-Cog, Donanemab, Amyotrophic lateral sclerosis, B cell, AMF, Incidence, III, Degenerative disease, Patient, Cholinesterase, Veterinary medicine, Medicine, MMSE, ALS, Alzheimer's disease, Organic, Mini–Mental State Examination, Scientific Committee on Antarctic Research, AB, University, AD, Disease, Multiple sclerosis, Research, Science, Memantine, Safety, PKI, Reno 1868 FC, Communication, Euronext Paris, Macrophage, Tyrosine kinase inhibitor, European Medicines Agency, Microglia, Central nervous system, AE, INT, Mast cell, Memory, Survival, Pharmaceutical industry, Dietary supplement, Vaccine, Copper, Neurodegeneration

The primary endpoint of study AB21004 will be to evaluate the effect of masitinib on absolute change from baseline in ADCS-ADL score and in ADAS-Cog-11.

Key Points: 
  • The primary endpoint of study AB21004 will be to evaluate the effect of masitinib on absolute change from baseline in ADCS-ADL score and in ADAS-Cog-11.
  • Furthermore, masitinib is an orally administered tyrosine kinase whereas the aforementioned anti-amyloid antibody drugs are administered via injection.
  • The trial (AB21004) aims to confirm the outcomes observed in the previous masitinib phase 2B/3 study (AB09004) supporting the efficacy and safety of masitinib.
  • Study AB09004 was the first successful phase 2B/3 randomized trial in mild-to-moderate Alzheimers disease of a drug targeting innate immune cells of the neuroimmune system.

Insights on the Alzheimer's Therapeutics Global Market to 2030 - by Drug Class, Distribution Channel and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Pharmaceutical, Health, Mental Health, Revenue, Cholinesterase, Memantine, Memory, Amnesia, Therapy, Disease, Thought, Prevalence, Population, Diagnosis, Organization, CAGR, Government budget balance, Research, Alzheimer's disease, Judgement, Investment, Dementia, Degenerative disease, R, World, Industry, Market share, Incidence, Awareness, World Health Organization, Pharmacy, Government, Death, Ageing, USD, Language, Healthcare, Pharmaceutical industry

The "Alzheimer's Therapeutics Market Share, Size, Trends By Drug Class, By Distribution Channel, By Region, Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alzheimer's Therapeutics Market Share, Size, Trends By Drug Class, By Distribution Channel, By Region, Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global alzheimer's therapeutics market size is expected to reach USD 14.20 billion by 2030, according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • Alzheimer's disease is a degenerative neurological condition where memory loss and cognitive impairment are brought on by the death of brain cells.

RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis

Retrieved on: 
Thursday, October 13, 2022
SLE, News, MG, Cholinesterase, NMPA, Disease, B-cell activating factor, Immunoglobulin G, Laboratory, Lupus, Glucocorticoid, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Muscle weakness, Patient, Social conditions in Honduras, Research, ODD, IgG4-related ophthalmic disease, Myasthenia gravis, Food, Immune system, Trial of the century, Company, National Medical Products Administration, CEO, FC, Nature, GMG, Thymectomy, SHA, Plasmapheresis, Environment, Speech, Eye, TACI, FDA, Autoimmunity, Neutralizing antibody, Solution, Pharmaceutical industry, Vaccine

YANTAI, China, Oct. 12, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) for its proprietary novel fusion protein Telitacicept (RC18) for the treatment of myasthenia gravis (MG).

Key Points: 
  • YANTAI, China, Oct. 12, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) for its proprietary novel fusion protein Telitacicept (RC18) for the treatment of myasthenia gravis (MG).
  • Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease which causes patients to be prone to fluctuating muscle weakness.
  • At present, the most common treatment options to alleviate symptoms for MG include cholinesterase inhibitors, glucocorticoids, immunosuppressants, intravenous immunoglobulin, plasma exchange, anti-CD20 monoclonal antibodies (mAbs), and thymectomy.
  • "We're delighted that the FDA has granted ODD for the RemeGen created proprietary novel fusion protein Telitacicept," said Dr. Jianmin Fang, CEO and Chief Scientific Officer of RemeGen.

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

Retrieved on: 
Tuesday, October 11, 2022
Lewy body, Medical school, Pharmacology, Memorial Sloan Kettering Cancer Center, Cholinesterase, Therapy, University of California, San Diego, Degenerative disease, Pfizer, Private Securities Litigation Reform Act, Vance DeGeneres, Retina, Antibody, Fasinumab, Research, Dementia, Nasdaq, Anesthesiology, Risk, Nerve growth factor, U.S. Securities and Exchange Commission, Department, CEO, Pain, Securities & Exchange Commission of Pakistan, Cognition, Forest Laboratories, Chemistry, DLB, CNS, Temple University, GLOBE, Intellectual property, Chronic pain, Stony Brook University, Eisai, Central nervous system, Regeneron Pharmaceuticals, Bachelor of Science in Human Biology, Pharmaceutical industry, Science, Philosophy

Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept and Namenda.

Key Points: 
  • Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept and Namenda.
  • Dr. Tiseo was most recently the executive director of clinical development at Centrexion Therapeutics, a private biotechnology company focused on the development of non-opioid drugs for the treatment of acute and chronic pain.
  • At Centrexion he worked with the clinical operations and regulatory teams to develop and execute strategies for the clinical development of the companys lead Phase 3 candidate as well as a pipeline of earlier stage therapeutics.
  • Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina.

AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease

Retrieved on: 
Monday, October 10, 2022
Medicine, Mini–Mental State Examination, Euronext Paris, Scientific Committee on Antarctic Research, Science, INT, ADAS, Lists of diseases, Sorbonne University, AMF, Population, Donanemab, ALS, Company, MMSE, Marketing, Neurology, Veterinary medicine, Incidence, Communication, Central nervous system, Macrophage, B cell, Research, Cell, Mast cell, Memantine, Degenerative disease, Microglia, PKI, Alzheimer's disease, Ageing, AD, Survival, Inflammation, Vacuum, Memory, Cholinesterase, Disease, Multiple sclerosis, ADAS-Cog, Cognition, Patient, Amyotrophic lateral sclerosis, III, MD, Safety, AE, AB, Tyrosine kinase inhibitor, Pharmaceutical industry, Medical imaging, Vaccine, Dietary supplement, Copper, Neurodegeneration

The objective of study AB21004 is to confirm treatment effect with masitinib 4.5 mg/kg/day as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.

Key Points: 
  • The objective of study AB21004 is to confirm treatment effect with masitinib 4.5 mg/kg/day as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.
  • Professor Bruno Dubois, MD, principal investigator of the study and Professor of Neurology at Sorbonne University, France commented, We are very excited to initiate this confirmatory phase III study with masitinib in Alzheimers disease.
  • There is a vacuum of treatment options for patients with mild or moderate Alzheimers disease.
  • The results from first phase 2B/3 study, AB09004, were very encouraging, especially considering this is a difficult to treat patient population.

Global Alzheimer's Therapeutics (Cholinesterase Inhibitors, Pipeline Drugs) Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Pharmaceutical, Health, Neurology, Alzheimer's Association, National Institute, Hospital, Alzheimer's disease, Research, AIM, Therapy, Biogen, BAN2401, National Institute on Aging, USD, Incidence, High society, Risk, Rush Alzheimer's Disease Center, Alzheimer's Society, Neglected tropical disease research and development, Chapter Three, Eli Lilly, Medicare, Cholinesterase, FDA, Company, Dementia, United Kingdom, AD, Association, Eli Lilly and Company, Society, Patient, Pharmaceutical industry, Medical imaging, Fine chemical

The "Global Alzheimer's Therapeutics Market Size, Share & Trends Analysis Report by Product (Cholinesterase Inhibitors, Pipeline Drugs), by End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Alzheimer's Therapeutics Market Size, Share & Trends Analysis Report by Product (Cholinesterase Inhibitors, Pipeline Drugs), by End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Government organizations are engaged in providing funds for Alzheimer's support, care, and research activities, which is projected to fuel the market growth.
  • For instance, in March 2022, the Alzheimer's Society announced to spend around USD 3.5 billion in the coming years on dementia research to improve the care of patients.
  • According to Alzheimer's Association report 2022, approximately 32% of total Medicare beneficiaries with Alzheimer's have at least one hospital discharge annually
    Chapter 3 Alzheimer's Therapeutics Market Variables, Trends & Scope